Alembic Pharmaceuticals ups its US game plan, acquires Orit

Drug firm Alembic Pharmaceuticals, which is over 100-year-old, started focusing on the US market a bit late. In the past three years, the company has not only increased its research and development (R&D) efforts for the US market but has acquired Orit, an oral solids and liquids manufacturing firm. Alembic has a 200-product grid for the US market, up from 40 in three years and expects to launch 10-12 products for the US market every year.

Having popular brands like Glycodin (cough syrup) in its kitty, Vadodara-headquartered Alembic had a domestic focus until a few years ago. Its first abbreviated